OBJECTIVES: To analyze the prevalence of ovarian cancers (OC) with consideration to BRCA1/2 genotype in the population of Russian women. To create a predictive model of the rate of inherited OC with respect to the stage of the disease. To assess the demand for screening programs for potential female patients (I-II degree relatives of patients with OC), who should be in the risk group for OC and undergo genetic testing. METHODS: The first stage of the study included data mining on the OC prevalence and morbidity in Russia, including patients with mutations in BRCA1/2 genes, and analysis of clinical recommendations on the course and outcomes of OC in different clinical groups of patients. On the next stage, we developed a clinical statistical model of OC and distinguished the group of patients subject to screening and treatment programs. RESULTS: In 2016, there are probably 362-486 persons with newly diagnosed patients with early stages of OC and mutation in BRCA1/2, and 1197-1437 persons with advanced OC. The prevalence of OC with BRCA1/2 mutation in this period is 10176-12095 persons. According to expert estimations, 1683-1762 relatives of patients are carriers of the mutation in BRCA1/2, and 673-705 will have OC during lifetime (0.4 risk of this subtype of OC). The survival rate in the „genotyped” group is 2.4 times higher than in the group without genotyping of relatives. CONCLUSIONS:  Genotyping for BRCA1/2 mutation is advised in all females with OC for clinical and economic reasons independent of their family history. The detection of relatives with BRCA mutations helps to avoid significant load on public budget in social security, and the load on health care budgets on various levels connected with the optimization of the existing treatment schedules.